Joerg Schlingemann
Overview
Explore the profile of Joerg Schlingemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas R, Ponting D, Thresher A, Schlingemann J, Wills J, Johnson G
Arch Toxicol
. 2025 Jan;
99(3):983-993.
PMID: 39751876
The tumorigenic dose 50 (TD) is a widely used measure of carcinogenic potency which has historically been used to determine acceptable intake limits for carcinogenic compounds. Although broadly used, the...
2.
Ponting D, Czich A, Felter S, Glowienke S, Harvey J, Nudelman R, et al.
Regul Toxicol Pharmacol
. 2024 Dec;
156:105762.
PMID: 39662665
The carcinogenic potency categorisation approach (CPCA) has recently been introduced by health authorities. In this model, structural features from recent literature, industry proposals, and analyses performed by health authorities, provide...
3.
Fine J, Allain L, Schlingemann J, Ponting D, Thomas R, Johnson G
Regul Toxicol Pharmacol
. 2023 Oct;
145:105505.
PMID: 37805106
N-nitrosamines (NAs) are a class of compounds of which many, especially of the small dialkyl type, are indirect acting DNA alkylating mutagens. Their presence in pharmaceuticals is subject to very...
4.
Burns M, Ponting D, Foster R, Thornton B, Romero N, Smith G, et al.
J Pharm Sci
. 2023 Oct;
112(12):3005-3011.
PMID: 37805074
N-Nitrosamines are a class of indirect acting mutagens, as their metabolic degradation leads to the formation of the DNA-alkylating diazonium ion. Following up on the in-silico identification of thousands of...
5.
Schlingemann J, Burns M, Ponting D, Martins Avila C, Romero N, Jaywant M, et al.
J Pharm Sci
. 2022 Nov;
112(5):1287-1304.
PMID: 36402198
This article reports the outcome of an in silico analysis of more than 12,000 small molecule drugs and drug impurities, identifying the nitrosatable structures, assessing their potential to form nitrosamines...
6.
Schlingemann J, Hickert S, Blom G, Kocks G, Allain L
Heliyon
. 2022 Jun;
8(6):e09607.
PMID: 35734570
Our letter to the editor of Heliyon outlines queries on the methodology and sample preparation used in article e06179, published in 2021. The nitrite measurements reported are higher than those...
7.
Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, et al.
J Pharm Sci
. 2022 May;
112(6):1615-1624.
PMID: 35500671
N-Nitrosamine risk assessment and control have become an integral part of pharmaceutical drug product development and quality evaluation. Initial reports of nitrosamine contamination were linked with the drug substance and...
8.
Schlingemann J, Boucley C, Hickert S, Bourasseau L, Walker M, Celdran C, et al.
Int J Pharm
. 2022 Apr;
620:121740.
PMID: 35421534
Since late 2019, concerns regarding trace levels of the probable human carcinogen N-dimethylnitrosamine (NDMA) in Metformin-containing pharmaceuticals have been an issue if they exceeded the maximum allowable intake of 96 ...
9.
Fritzsche M, Blom G, Keitel J, Goettsche A, Seegel M, Leicht S, et al.
Eur J Pharm Sci
. 2021 Oct;
168:106026.
PMID: 34597792
Background: For nearly three years, the concerns regarding trace levels of N-nitrosamines in pharmaceuticals and the associated cancer risk have significantly expanded and are a major issue facing the global...
10.
Schlingemann J, Leijon M, Yacoub A, Schlingemann H, Zohari S, Matyi-Toth A, et al.
J Virol Methods
. 2009 Sep;
163(1):116-22.
PMID: 19751768
Recent outbreaks of avian influenza in different parts of the world have caused major economic losses for the poultry industry, affected wildlife seriously and present a significant threat even to...